Literature DB >> 3407028

Dornier extracorporeal shock-wave lithotripsy for ureteral stones.

A D Jenkins1.   

Abstract

Most investigators think that ESWL is the preferred method for treating calculi in the upper ureter--that segment proximal to the superior margin of the iliac crest. Ureteroscopic manipulation, percutaneous antegrade manipulation, and open ureterolithotomy are secondary choices. The treatment of calculi in the lower ureter--that segment between the upper border of the iliac crest and the ureterovesical junction--is somewhat controversial. Most urologists favor ureteroscopic manipulation: small stones can be extracted, while larger stones can be fragmented with ultrasonic, electrohydraulic, or even laser lithotripsy. However, manipulation in the presacral ureter is more difficult than in the juxtavesicular ureter, and all stones are not amenable to ureteroscopic management. Our experience at the University of Virginia led us to use ESWL for lower ureteral stones when ureteroscopic manipulation fails or cannot safely be accomplished or when patients refuse cystoscopy. Juxtavesicular stones are treated with a minor modification (sitting position) of standard supine ESWL, whereas presacral stones are treated with prone ESWL.

Entities:  

Mesh:

Year:  1988        PMID: 3407028

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

1.  In situ prone ESWL for the treatment of lower ureteral stones: experience with 28 patients.

Authors:  I Başar; T Gürpinar; A Erkan
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  In situ extracorporeal shock wave lithotripsy for upper ureteral stones: experience with 65 patients.

Authors:  I Başar; T Gürpinar; A Erkan
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

3.  Shock wave lithotripsy for distal ureteric stones: supine or prone.

Authors:  Mustafa Okan Istanbulluoglu; Mustafa Burak Hoscan; Mehmet Ilteris Tekin; Tufan Cicek; Bulent Ozturk; Hakan Ozkardes
Journal:  Urol Res       Date:  2010-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.